From a clinical perspective, the sensitisation of CLL cells to killing by bendamustine that was observed when the AKT inhibitor was added to the CD154 co-culture system provides a strong rationale for combining AKT inhibitors with chemotherapy-based treatment in order to augment cytoreduction at sites of tissue involvement. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.